Meeder Asset Management Inc Assembly Biosciences, Inc. Transaction History

Meeder Asset Management Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 02, 2020	SELL	$15.08 - $27.04 $11,023 - $19,766	-731 Closed	0 $0
Q2 2020 Aug 11, 2020	BUY	$14.57 - $23.96 $6,483 - $10,662	445 Added 155.59%	731 $16,000
Q1 2020 May 15, 2020	SELL	$10.27 - $21.23 $6,151 - $12,716	-599 Reduced 67.68%	286 $4,000
Q4 2019 Feb 13, 2020	SELL	$8.36 - $23.81 $944 - $2,690	-113 Reduced 11.32%	885 $17,000
Q3 2019 Oct 17, 2019	BUY	$9.83 - $14.82 $6,065 - $9,143	617 Added 161.94%	998 $10,000
Q1 2019 Apr 16, 2019	SELL	$17.7 - $24.93 $1,752 - $2,468	-99 Reduced 20.63%	381 $8,000
Q4 2018 Jan 17, 2019	BUY	$19.05 - $36.45 $6,362 - $12,174	334 Added 228.77%	480 $11,000
Q3 2018 Nov 02, 2018	BUY	$34.41 - $44.23 $4,198 - $5,396	122 Added 508.33%	146 $0
Q2 2018 Jul 24, 2018	SELL	$39.21 - $50.29 $3,999 - $5,129	-102 Reduced 80.95%	24 $0
Q1 2018 May 03, 2018	BUY	$41.7 - $64.16 $2,627 - $4,042	63 Added 100.0%	126 $6,000
Q4 2017 Feb 02, 2018	BUY	$28.58 - $49.91 $1,800 - $3,144	63	63 $2,000

16.3K

Ticker ASMB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,436,900
Market Cap $766M
Description
Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also deve...

Get notified when there are updates to the investment portfolio of Meeder Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Meeder Asset Management Inc with notifications on news.